Sign In
Buy DGNOF
$0.158
-0.0041 (-2.54%)
At Close: Jun 03, 2026
DIAGNOS Announces Closing of Private Placement
03:53pm, Friday, 20'th Sep 2024
BROSSARD, Quebec, Sept. 20, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues thr
DIAGNOS Announces Date of Annual General and Special Meeting of Shareholders
03:45pm, Thursday, 22'nd Aug 2024
BROSSARD, Quebec, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues throug
DIAGNOS Successfully Completes ISO 13485 / MDSAP Audit and receives its certification to move forward with FDA and Health Canada
09:45am, Tuesday, 20'th Aug 2024
BROSSARD, Quebec, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues throug
DIAGNOS Announces Closing of Second and Final Tranche of Private Placement
05:07pm, Wednesday, 05'th Jun 2024
BROSSARD, Quebec, June 05, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues thro
BROSSARD, Quebec, May 21, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues throu
DIAGNOS Announces Closing of First Tranche of Private Placement
04:15pm, Thursday, 09'th May 2024
BROSSARD, Quebec, May 09, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues throu
DIAGNOS to Present Cutting-Edge AI Solutions for Retinal Health at ARVO 2024
09:00am, Monday, 06'th May 2024
BROSSARD, Quebec, May 06, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Company”) (TSX Venture: ADK) (OTCQB: DGNOF), a provider of healthcare services in early detection of certain
BROSSARD, Quebec, April 16, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Company”) (TSX Venture: ADK) (OTCQB: DGNOF), a provider of healthcare services in early detection of certai
DIAGNOS Inc. to Present at the AI & Technology Hybrid Investor Conference April 11th
10:10am, Tuesday, 09'th Apr 2024
MONTREAL, April 09, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (ADK TSX: OTCQB: DGNOF), based in Montreal, Canada, focused on Artificial Intelligence for the medical market, today announced that André Lar
DIAGNOS Announces Grant of Stock Options
02:26pm, Wednesday, 03'rd Apr 2024
BROSSARD, Quebec, April 03, 2024 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues th
DIAGNOS Announces Grant of Stock Options
02:13pm, Wednesday, 03'rd Apr 2024
BROSSARD, Quebec, April 03, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the
DIAGNOS Welcomes Dr. Philippe Couillard to its Board of Directors
09:59am, Tuesday, 02'nd Apr 2024
BROSSARD, Quebec, April 02, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the
DIAGNOS Announces Closing of Second and Final Tranche of
05:45pm, Friday, 22'nd Mar 2024
BROSSARD, Quebec, March 22, 2024 (GLOBE NEWSWIRE) — DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues th
DIAGNOS Announces Closing of Second and Final Tranche of Private Placement
04:16pm, Friday, 22'nd Mar 2024
BROSSARD, Quebec, March 22, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues thr
DIAGNOS Announces Grant of Stock Options
03:45pm, Monday, 04'th Mar 2024
BROSSARD, Quebec, March 04, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the
